Physician profile
Benjamin T Carter
NPI 1902868961
$6,821.42
in general payments reported to CMS, 2019-2025
33 companies · $706 in 2025
The $706 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $765 · 2021: $838 · 2022: $903 · 2023: $1,471 · 2024: $1,279 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,215.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,188.81 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $961.52 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $854.04 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $411.43 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.67 | 2019-2024 | Ofev |
| Lilly USA, LLC | $329.57 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $296.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $142.05 | 2021-2024 | Verquvo, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $137.94 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.38 | 2019-2023 | Xifaxan |
| Amgen INC. | $78.11 | 2020-2024 | Repatha, Otezla |
| Allergan, INC. | $73.50 | 2020 | |
| Hydrofera LLC | $65.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.97 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.03 | 2019-2024 | Eliquis |
| Medtronic, INC. | $56.49 | 2023-2024 | Intellis Adaptivestim, Interstim |
| Sanofi-Aventis U.S. LLC | $50.51 | 2019 | |
| Dexcom, INC. | $41.63 | 2021-2022 | |
| Astellas Pharma US INC | $41.22 | 2019-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $37.19 | 2024 | Voquezna |
| Mylan Specialty L.P. | $34.60 | 2019-2023 | Yupelri |
| Sanofi Pasteur INC. | $29.27 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $25.17 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.32 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.76 | 2024 | |
| Sunovion Pharmaceuticals INC. | $17.68 | 2021 | |
| Abbott Laboratories | $17.24 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.01 | 2023 | Gemtesa |
| Inari Medical, INC. | $14.21 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.